Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kimberly Clark Corp (KMB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Kimberly Clark CorpTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Kimberly Clark Corp vs Zimmer Biomet Holdings Inc — how do they compare? Kimberly Clark Corp trades at $109.35 (market cap $36.11B), while Zimmer Biomet Holdings Inc trades at $96.43 (market cap $18.55B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.

KMBZBH
Market Cap
$36.11B$18.55B
Sector
Consumer StaplesHealth
52-Week High
$134.81$107.71
52-Week Low
$93.05$79.58
Enterprise Value
$41.67B$25.61B
Dividend Yield
4.72%0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kimberly Clark Corp

Kimberly-Clark (KMB) trades at $109.47, up 1.34% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings missed estimates due to China diaper disruptions and a distribution center fire, though gross margin expanded. The company maintains a strong dividend yield of 4.7% and an A credit rating. Analyst consensus is a $113.20 price target with 29% buy ratings, but near-term headwinds include softer consumer demand and inventory adjustments.

Outlook remains cautious with 2026 guidance trimmed; the stock offers value at a forward P/E of 14.6x and robust cash flow, but risks from China market volatility and input cost pressures persist. Institutional interest is mixed, with recent filings showing both new positions and trims. Long-term prospects hinge on innovation and productivity gains offsetting cyclical challenges.

Zimmer Biomet Holdings Inc

ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.

The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kimberly Clark Corp

With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Read more on KMB

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH